In prostate cancer cells, OPREA-LAGER et al. have showed that the docetaxel-resistant MLL cells are found to highly express ABCC4 and that functional repression of ABCC4 in MLL cells causes a marked reduction in effective concentration of docetaxel and exhibited an improved therapeutic efficacy [30]. This evidence concerns the gene KMT2A and prostate carcinoma.